Nice Bids coming ..Bigger Jumps coming once we break the $1 Mark which could happen this week .New Partner Deal expected within 4 weeks .GL http://www.otcmarkets.com/stock/IGXT/quote
NICE move again but real RALLY will start once we break the $1 Mark ...GL http://ih.advfn.com/p.php?pid=webchart&symbol=IGXT&period=0&size=19&volume=1
Thanks Guys .. The heavy MM manipulation today created another great buying opportunity . Partner deal news which is expected within this month will push the stock much much higher .
IntelGenx Technologies Corp (OTCMKTS:IGXT) On The Verge Of A Breakout http://www.insiderfinancial.com/int...tcmktsigxt-on-the-verge-of-a-breakout/116919/
Im back in this one because a lot of good news is on the way see below . Tadalafil a thin-film version of the blockbuster drug Cialis could enter the market up to2-3 years before the generics which is MEGA News for Intelgenx .US-NDA submission for Tadalafil expected 4-8 weeks and there is strong partner interest for the drug term sheet already received .I think now is a very good entry point .GL Market Cap :$46 Million Cash: Untill 2021+ (including convertible debt) Price: 0.72 NDA submission for tadalafil in June or July NDA resubmission for Rizaport in July or August Partnership for Tadalafil in 2H 2017 http://www.biotuesdays.com/features...-multi-faceted-bd-approach-for-its-oral-films IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition. transcript may 2017 http://s2.q4cdn.com/790425727/files...x-corp-q1-2017-financial-results-18899915.pdf The trial with the ANDA applicants that submitted applications for generic copies, is scheduled for July. Some of the ANDA applicants have already settled with Lilly, settled in the sense that they have greed to launch their generic product only at the expiry of this third patent, the dosing patent that we obtained a license for. That means that we have a pretty good chance to enjoy an extended period of excessivity once we’ve launched our product. Several companies have expressed interest in licensing the product. Term sheets(phon)have been submitted and are currently being reviewed and the due-diligence process has commenced.
Good News and more to come IntelGenx Announces Issuance of US Patent for Topical Oral Film Technology June 08, 2017 http://www.intelgenx.com/investors/...for-Topical-Oral-Film-Technology/default.aspx IntelGenX on the way to take some of the $16bn thin films market https://investorintel.com/sectors/biotech/biotech-intel/intelgenx-thin-film-market/
Market Cap : $48 Million / Profitability expected in 2018 /very low burn-rate of $600-700K a Quarter / Cash untill 2021+ (including convertible debt) , if everything goes well then this stock could run to $10 even then it wouldnt be expensive = Very attractive and underpriced Pharma Play. NDA submission for Tadalafil (erectile dysfunction) in June or July >> FDA approval in 1H 2018 (Peak Sales $120-150 Million) NDA REsubmission for Rizaport(Migraine) in July or early August >> FDA approval 1Q 2018 (Peak Sales $50-60 Million) Patent ruling regarding the Par Pharma Drug (opioid dependence) in June 2017 >> Market Launch expected in 1H 2018 (Peak Sales $70-80 Million) Start Phase 2a for Montulukast (Alzheimer disease) in June >> Phase 2a Results in 4Q 2017 (BLOCKBUSTER Candidate) MEGA Pipeline http://s2.q4cdn.com/790425727/files...uct-Portfolio-and-Pipeline-June-2017.xlsx.jpg Presentation http://s2.q4cdn.com/790425727/files/doc_presentations/2017/Investor-presentation-EN-June-5.pdf
Major breakout imminent ,stock is only a few cents from multiple year high away https://stockcharts.com/c-sc/sc?s=igxt&p=D&yr=0&mn=9&dy=0&i=p93834726544&r=3658
Looks like big breakout is around the corner ---- IntelGenx Receives USPTO Notice of Allowance for Oral Film Dosage Form Technology Patent http://www.marketwired.com/press-re...form-technology-patent-otcqx-igxt-2223907.htm
The company today announced that the United States Patent and Trademark Office ("USPTO") has granted a notice of allowance for US Patent Application 13/748,241, entitled "Solid oral film dosage forms and methods for making same." Shares was up over 7% with good volume today. Looking for breakout at 1.09 for a run up to 1.27. http://www.allotcbb.com/quote.php?symbol=igxt
Here Are Three Near Term Catalysts To Watch From IntelGenx Technologies Corp https://insiderfinancial.com/intelgenx-technologies-corp-otcmktsigxt-has-a-july-full-of-catalysts
On July 12, IntelGenx Presents at BIT's 7th Annual International Symposium of Drug Delivery Systems. http://www.allotcbb.com/quote.php?symbol=igxt
Great time to load up nowafter they resubmit the NDA for Rizaport early this week .GL RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines..November 1, 2017 https://finance.yahoo.com/news/redhill-biopharma-intelgenx-submit-drug-110100087.html Market Cap : US$48 Million / Cash US$8.2 million /very low burn-rate of ~$700K a Quarter =Cash untill 2020+ EXCLUDING payments from new partnerships ,profitability expected quickly with approval for Rizaport and Tadalafil both approval expected in 2018, if everything goes well then this stock could run to $10 even then it wouldnt be expensive . Intelgenx (IGXT) Markt-Cap $48 Million Cash 8.1 Million Price: $0.73 FDA Decision for Rizaport(Migraine) in Q2/2018 (Peak Sales $60-80 Million) NDA submission for Tadalafil (erectile dysfunction) this Quarter >> FDA approval in 2H 2018 (Peak Sales $150++ Million) Start Phase 2a for Montulukast (Alzheimer disease) this Quarter >> Phase 2a Results in 1H/2018 (Potential BLOCKBUSTER Drug) Opioid dependence drug partnered with Par Pharma >> FDA approval depends on patent ruling (Peak Sales $100++ Million) 30-Month Stay already expired MEGA Pipeline http://s2.q4cdn.com/790425727/files...-Product-Portfolio-and-Pipeline-July-2017.jpg Presentation http://s2.q4cdn.com/790425727/files...TELGENX-Presentation-September-2017_final.pdf https://investorintel.com/sectors/biotech/biotech-intel/intelgenx-thin-film-market/
The companies received a CRL in March 2013 in response to their original filing citing the need for more information related to third party chemistry, manufacturing and controls (CMC) and packaging/labeling. No additional safety or efficacy data were required. If accepted for review, the agency's action date should be in H1 2018.
MACD goes green, bullish cross in Stochastic oscillator and RSI stands at 52.274 level with positive bias. On watch for clear above 0.7665. http://www.allotcbb.com/quote.php?symbol=igxt
IGXT = MC $49 M / $13 M Cash / FDA Decision for Migraine Drug on APRIL 1 / HOT Cannabis Play has Deal with TILRAY (TLRY) / UNDISCOVERED Stock = great buying opp here with 200-300% upside potential IGXT announced that the FDA has accepted the resubmission of 505(b)(2) new drug application (NDA) for Rizaport oral soluble film 10 mg, which is being developed for the treatment of acute migraine. The FDA has set an action date of Apr 1, 2019. IntelGenx: A Small Cap With A Big Pipeline In Cannabis, Alzheimer's, And ED https://seekingalpha.com/article/4208382-intelgenx-small-cap-big-pipeline-cannabis-alzheimers-ed Presentation http://s2.q4cdn.com/790425727/files.../Nov-2018-IntelGenx-Investor-Presentation.pdf [/IMG]
